Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1987;73(1):12-8.
doi: 10.1007/BF00695496.

Relationship of adjuvants and swine influenza vaccine to experimental neuropathy in rabbits

Relationship of adjuvants and swine influenza vaccine to experimental neuropathy in rabbits

H C Powell et al. Acta Neuropathol. 1987.

Abstract

Experimental neuropathy, characterized by endoneurial edema and demyelination, was induced by inoculating rabbits with a combination of Freund's complete adjuvant (FCA), gangliosides, lecithin and cholesterol. A less severe demyelinating neuropathy could be induced by treatment with FCA alone but no significant change could be elicited by injection of swine influenza vaccine (SFV) alone. When FCA was combined with gangliosides, lecithins, cholesterol and SFV, neuropathy occurred, but the changes were less severe than if these agents were used without SFV. Sera were tested for myelin basic protein (MBP) and galactocerebroside (GC) antibodies in each experimental group. Neither SFV alone nor SFV combined with Freund's complete adjuvant, gangliosides, cholesterol and lecithin evoked significant antibody titers to MBP or GC. However, rabbits inoculated with FCA, gangliosides, lecithin and cholesterol had rising titers of antibody to both MBP and GC over the 3-month experimental period. One rabbit inoculated with FCA alone had significant antibody to MBP. The findings suggest that Freund's complete adjuvant alone can induce demyelination in the peripheral nerves of rabbits and that SFV may modulate the immune response acting either as an adjuvant or suppressant in the experimental demyelinating disease.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Lipids. 1986 May;21(5):342-6 - PubMed
    1. J Immunol. 1984 Oct;133(4):1946-50 - PubMed
    1. Am J Epidemiol. 1978 May;107(5):433-8 - PubMed
    1. Acta Neuropathol. 1977 Oct 10;40(2):103-10 - PubMed
    1. Lab Invest. 1969 Feb;20(2):127-38 - PubMed

Publication types

MeSH terms

LinkOut - more resources